Loading...
MOR logo

MorphoSys AGNasdaqGS:MOR Stock Report

Market Cap US$2.8b
Share Price
n/a
US$17.86
n/aintrinsic discount
1Y150.8%
7D1.9%
Portfolio Value
​
View

MorphoSys AG

NasdaqGS:MOR Stock Report

Market Cap: US$2.8b

MorphoSys (MOR) Stock Overview

Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. More details

MOR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Revenue is forecast to grow 24.99% per year

Risk Analysis

Negative shareholders equity

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


MOR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

MorphoSys AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for MorphoSys
Historical stock prices
Current Share Price€18.96
52 Week High€19.50
52 Week Low€4.19
Beta0.67
1 Month Change1.94%
3 Month Change5.69%
1 Year Change150.79%
3 Year Change38.65%
5 Year Change-36.95%
Change since IPO-26.57%

Recent News & Updates

Recent updates

Seeking Alpha • May 01

MorphoSys: Hold Rating Until The Novartis Deal Closes

Summary MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals received and successful precedents of similar M&A transactions. Pelabresib, MorphoSys's leading candidate for myelofibrosis treatment, shows promising results and potential as a game-changer in the field. We downgrade to a hold rating, although, we believe the deal will close in 1H 2024. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Novartis And MorphoSys Are A Perfect Match

Summary Novartis plans to acquire MorphoSys, a German biopharmaceutical company, for EUR 2.7 billion in cash. The acquisition will give Novartis access to MorphoSys' extensive oncological pipeline, including the potentially game-changing treatment option for myelofibrosis, pelabresib. Novartis has a strong financial position and the capacity to comfortably fund the acquisition, demonstrating its readiness to enhance its oncology portfolio. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Summary Shares of biotech company MorphoSys have been climbing due to the approval chances of its lead candidate, pelabresib, for the treatment of myelofibrosis. MorphoSys co-markets and sells the drug Monjuvi in the US, which is used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma. Despite some mixed data and intense competition, analysts believe pelabresib could reach peak annual sales of over $1.5 billion, which would significantly increase MorphoSys' valuation and share price. The Munich based biotech took a substantial risk to acquire Constellation Pharma, developer of Pelabresib, in a $1.7bn deal. After a torrid bear run on the stock, MorphoSys may finally be ready to deliver upside in 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys (NASDAQ:MOR) trades 12.8% down premarket after it provided updated financial guidance based on prelim consolidated results for the first six months 2022 and post the recent licensing agreements with Human Immunology Biosciences for felzartamab and MOR210. Preliminary Monjuvi (tafasitamab-cxix) U.S. Net Product Sales stood at $23.3M (€21.7 million) for Q2 of 2022 and $41.9M (€38.3M) for 1H22. For FY22, MorphoSys now expects Monjuvi U.S. Net Product Sales in the range of $90 to $110M (previously: $110 to $135M). It sees R&D expenses in the range of €275 to €300M (previously: €300 to €325M) and SG&A expenses in the range of €150 to €165M (previously: €155 to €170M). Guidance for Gross Margin for Monjuvi U.S. Net Product Sales remains unchanged. The previous financial guidance for 2022 was provided by MorphoSys on Jan. 7, 2022 and reaffirmed on Mar. 16 2022 and May 4, 2022.
Seeking Alpha • May 04

MorphoSys May Not Recover From Adventurous Constellation Buyout

MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly.
Seeking Alpha • Jan 28

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Sierra Oncology got a boost on Monday, releasing some very strong data in relation to its lead asset Momelotinib. The drug - indicated for Myelofibrosis - looks like it can match standard of care Jakafi, and improve upon the latter's record amongst patients suffering with anemia. If approved, although it will take time, Sierra may have a blockbuster drug (>$1bn sales per annum) on its hands. Meanwhile, Morphosys stock has had a tough time ever since the German biotech acquired Constellation to get hold of its BET inhibitor Pelabresib - indicated for Myelofibrosis. Morphosys has co-developed a drug - Monjuvi - with Incyte, who market and sell Jakafi - in combo with Pelabresib, Jakafi may be able to resist the challenge from Momelotinib.

Shareholder Returns

MORUS BiotechsUS Market
7D1.9%1.2%2.1%
1Y150.8%41.9%30.6%

Return vs Industry: MOR exceeded the US Biotechs industry which returned 14.8% over the past year.

Return vs Market: MOR exceeded the US Market which returned 15.9% over the past year.

Price Volatility

Is MOR's price volatile compared to industry and market?
MOR volatility
MOR Average Weekly Movement3.3%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: MOR has not had significant price volatility in the past 3 months.

Volatility Over Time: MOR's weekly volatility has decreased from 12% to 3% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992464Arkadius Pichotawww.morphosys.com

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.

MorphoSys AG Fundamentals Summary

How do MorphoSys's earnings and revenue compare to its market cap?
MOR fundamental statistics
Market capUS$2.78b
Earnings (TTM)-US$513.62m
Revenue (TTM)US$264.68m
10.5x
P/S Ratio
-5.4x
P/E Ratio

Is MOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MOR income statement (TTM)
Revenue€241.47m
Cost of Revenue€60.14m
Gross Profit€181.33m
Other Expenses€649.90m
Earnings-€468.57m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 07, 2024

Earnings per share (EPS)-12.44
Gross Margin75.09%
Net Profit Margin-194.05%
Debt/Equity Ratio-658.0%

How did MOR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 18:56
End of Day Share Price 2024/08/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MorphoSys AG is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olav ZilianBaader Helvea Equity Research
Brian BalchinBarclays
Rosie TurnerBarclays